Myovant Sciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.06.20	NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps (RTTNews)
01.06.20	Stock Alert: Myovant Sciences Trading Up 18% (RTTNews)
23.04.20	IMMU Gets Early FDA Nod, KNSA's PN Trial Meets Goals, MYOV In Good Spirits (RTTNews)
22.04.20	Stock Alert: Myovant Sciences Stock Up 4% In Premarket (RTTNews)
22.04.20	LIFE In COVID-19 Battle, LH On Watch, CARA Keeps KALM, All Eyes On MYOV (RTTNews)
24.03.20	9 Pharma/Biotech Stocks To Watch This Week, Here's Why... (RTTNews)
10.02.20	Stock To Watch: Myovant Sciences (MYOV) (RTTNews)
10.02.20	Stock Alert: Myovant Sciences Jumps After Positive Relugolix Data (RTTNews)
03.02.20	Stock Alert: Myovant Sciences Shares Fall (RTTNews)
25.11.19	MYOV Up Over 130% In 5 Days, What's Next? (RTTNews)
19.11.19	Myovant: Relugolix Phase 3 Study Meets Endpoints In Advanced Prostate Cancer (RTTNews)
19.11.19	Watch Out For Tuesday - Will Myovant's HERO Prove Its Mettle? (RTTNews)
01.11.19	Today's Top 5 Gainers In Healthcare Sector (ELOX, STAA, MYOV…) (RTTNews)
14.05.19	Myovant's Drug To Treat Uterine Fibroids Hits Key Goals In Phase III Study (RTTNews)
16.04.19	AXSM Has Had An Awesome Run. What Awaits These 13 Biotech Stocks In Q2, 2019? (RTTNews)
14.02.19	7 Top Gainers In Healthcare Sector (PTX, MYOV, DXR...) (RTTNews)
12.07.18	AKCA Gets EC Nod, FDA Panel To Review Malaria Drug Today, OVID Awaits Data In Q3 (RTTNews)
18.06.18	Myovant Sciences to Present at First Annual Roivant Pipeline Day (PR Newswire)
07.06.18	Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018 (PR Newswire)
14.03.18	GTHX Hits Record High, BVX Q4 Revenue Up 20%, ASNS Catches Eyes (RTTNews)
06.03.18	Myovant Sciences to Present at Upcoming Investor Conferences (PR Newswire)
13.02.18	Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017 (PR Newswire)
09.11.17	Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids (PR Newswire)
03.10.17	Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids (PR Newswire)
31.08.17	Myovant Sciences Announces Upcoming Presentation at Baird's 2017 Global Healthcare Conference (PR Newswire)
10.08.17	Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017 (PR Newswire)
19.07.17	Myovant Bolsters Executive Team with Key Management Appointments (PR Newswire)
10.07.17	Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman (PR Newswire)
29.06.17	Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Endometriosis-Associated Pain (PR Newswire)
26.06.17	Virtus Global Dividend & Income Fund Inc. Announces Preliminary Results of Tender Offer (PR Newswire)
24.05.17	Myovant Sciences Announces Presentation of Data at the European Congress of Endocrinology from Phase 2 Extension Study Evaluating Relugolix in Women with Endometriosis-Associated Pain (PR Newswire)
19.05.17	Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Endometriosis-Associated Pain at the World Congress on Endometriosis (PR Newswire)
18.05.17	Myovant Sciences Announces Upcoming Presentations of Relugolix Data from Phase 2 Trial in Women with Endometriosis-Associated Pain (PR Newswire)
07.05.17	Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Heavy Menstrual Bleeding and Uterine Fibroids at the Annual Meeting of the American Congress of... (PR Newswire)
27.02.17	Myovant Sciences to Present at Upcoming Investor Conferences (PR Newswire)
25.01.17	Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Myovant Sciences Ltd Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten